With Democrat In White House, “More Aggressive” FDA Comes Into Focus
This article was originally published in The Tan Sheet
Executive Summary
Democratic control of the White House, Senate and House brings the potential of a "more aggressive" FDA into sharp focus
You may also be interested in...
FDA Press Office Shakeup Startles Ousted Staffers
A young FDA official's decision to boot three seasoned press specialists from the Public Affairs Office may be an embarrassment for the agency.
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
Coalition asks for agency leader with industry experience
The Department of Health and Human Services secretary-designate should not disqualify FDA commissioner candidates "due to relationships with industry during the course of his/her career," a group of health organizations called the "FDA Commissioner Coalition" in media reports says in a letter to former Sen. Tom Daschle. Experience within "an FDA-regulated industry should be viewed as a positive qualification," as should solid scientific credentials, the ability to build consensus and a commitment to advance evidence-based science in the area of drug development, says the coalition, which includes groups with industry ties. Biotechnology and pharmaceutical stakeholders voiced concern over the Obama administration leaning toward an FDA head hostile to industry (1"The Tan Sheet" Nov. 10, 2008, p. 3). Groups signing the letter include the Alliance for Aging Research, the American Cancer Society and WomenHeart